Body Composition and Acute Stroke

NCT06589297 | Recruiting DMC

• 1 other identifier: CHUO-2024-04
• Study Type: interventional
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

Body composition appears to be a prognostic factor for the severity and functional outcome of stroke patients. In this study the prognostic value of two bioimpedance parameters will be studied (skeletal mass index and phase angle) and two temporal muscle measurements (thickness and surface area) to predict the functional outcome of patients at discharge and at 6 months

Conditions

Acute Stroke

Keywords

Stroke; Body composition; Bioimpedancemetry; Temporal muscle; Sarcopenia

Outcome Measures

Primary Outcomes (3)

• phase angle

  72 hours after stroke

• thickness of temporal muscle

  72 hours after stroke

• surface area of temporal muscle

  72 hours after stroke

Secondary Outcomes (3)

• Modified Rankin Scale (mRS)

  Month 6

• Modified Rankin Scale (mRS)

  Through month 3

• skeletal muscular Index

  72 hours after stroke

Study Arms (1)

Acute stroke patients

OTHER

Acute stroke patients

Diagnostic Test: Modified Rankin scale

Interventions

Modified Rankin scale DIAGNOSTIC_TEST

Acute stroke patients will undergo modified rankin scale

Acute stroke patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• volunteer stroke patients in acute phase
• Age ≥ 18 years
• Having had a brain MRI
• Able to understand assessment guidelines
• Not having objected to participate in the study after being duly informed

You may not qualify if:

• Person under tutorship or curatorship
• Person under court protection
• Persons deprived of their liberty
• Pregnant or breastfeeding women
• Have a pacemaker or defibrillator

Sponsors & Collaborators

• Centre Hospitalier Régional d'Orléans: lead

Study Sites (1)

CHU d'ORLEANS

Orléans, 45067, France

RECRUITING

Related Publications (7)

• Amir A, Pittel Z, Shahar A, Fisher A, Heldman E. Cholinotoxicity of the ethylcholine aziridinium ion in primary cultures from rat central nervous system. Brain Res. 1988 Jun 28;454(1-2):298-307. doi: 10.1016/0006-8993(88)90830-x.

  PMID: 3409012 BACKGROUND

• Nozoe M, Kubo H, Kanai M, Yamamoto M, Okakita M, Suzuki H, Shimada S, Mase K. Reliability and validity of measuring temporal muscle thickness as the evaluation of sarcopenia risk and the relationship with functional outcome in older patients with acute stroke. Clin Neurol Neurosurg. 2021 Feb;201:106444. doi: 10.1016/j.clineuro.2020.106444. Epub 2021 Jan 1.

  PMID: 33395619 BACKGROUND

• Katsuki M, Kakizawa Y, Nishikawa A, Yamamoto Y, Uchiyama T, Agata M, Wada N, Kawamura S, Koh A. Temporal Muscle and Stroke-A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume. Nutrients. 2022 Feb 6;14(3):687. doi: 10.3390/nu14030687.

  PMID: 35277046 BACKGROUND

• Li YX, Hou J, Liu WY. Long-term prognostic significance of sarcopenia in acute ischemic stroke. Medicine (Baltimore). 2022 Aug 26;101(34):e30031. doi: 10.1097/MD.0000000000030031.

  PMID: 36042682 BACKGROUND

• Nagano A, Shimizu A, Maeda K, Ueshima J, Inoue T, Murotani K, Ishida Y, Mori N. Predictive Value of Temporal Muscle Thickness for Sarcopenia after Acute Stroke in Older Patients. Nutrients. 2022 Nov 27;14(23):5048. doi: 10.3390/nu14235048.

  PMID: 36501078 BACKGROUND

• Dubinski D, Won SY, Mattes I, Trnovec S, Behmanesh B, Cantre D, Baumgarten P, Dinc N, Konczalla J, Wittstock M, Freiman TM, Gessler F. Frailty in cerebellar ischemic stroke-The significance of temporal muscle thickness. Front Neurol. 2023 Sep 26;14:1193685. doi: 10.3389/fneur.2023.1193685. eCollection 2023.

  PMID: 37822528 BACKGROUND

• Namgung HG, Hong S, Choi YA. Association of Temporalis Muscle Mass with Early Cognitive Impairment in Older Patients with Acute Ischemic Stroke. J Clin Med. 2023 Jun 15;12(12):4071. doi: 10.3390/jcm12124071.

  PMID: 37373767 BACKGROUND

MeSH Terms

Conditions

Stroke; Sarcopenia

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Marc VERIN, PUPH

  CHU ORLEANS

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marc VERIN, PUPH

CONTACT

0238651369; marc.verin@chu-orleans.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2024
• First Posted: September 19, 2024
• Study Start: October 10, 2024
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028
• Last Updated: February 2, 2026

Record last verified: 2026-01

Locations

FR (1)